Keytruda® (pembrolizumab) – New indication
June 24, 2020 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
Download PDF
